CN1199956C - 具有抗癌作用的噁二唑衍生物 - Google Patents

具有抗癌作用的噁二唑衍生物 Download PDF

Info

Publication number
CN1199956C
CN1199956C CNB018112404A CN01811240A CN1199956C CN 1199956 C CN1199956 C CN 1199956C CN B018112404 A CNB018112404 A CN B018112404A CN 01811240 A CN01811240 A CN 01811240A CN 1199956 C CN1199956 C CN 1199956C
Authority
CN
China
Prior art keywords
alkyl
replaces
compound
optional
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018112404A
Other languages
English (en)
Chinese (zh)
Other versions
CN1436179A (zh
Inventor
吉冈贵幸
前川隆司
渡边文彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of CN1436179A publication Critical patent/CN1436179A/zh
Application granted granted Critical
Publication of CN1199956C publication Critical patent/CN1199956C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNB018112404A 2000-04-21 2001-04-16 具有抗癌作用的噁二唑衍生物 Expired - Fee Related CN1199956C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP120234/2000 2000-04-21
JP2000120234 2000-04-21

Publications (2)

Publication Number Publication Date
CN1436179A CN1436179A (zh) 2003-08-13
CN1199956C true CN1199956C (zh) 2005-05-04

Family

ID=18631080

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018112404A Expired - Fee Related CN1199956C (zh) 2000-04-21 2001-04-16 具有抗癌作用的噁二唑衍生物

Country Status (16)

Country Link
US (2) US6720343B2 (enExample)
EP (1) EP1277744A4 (enExample)
JP (1) JP3974781B2 (enExample)
KR (1) KR100542780B1 (enExample)
CN (1) CN1199956C (enExample)
AU (2) AU2001246916B2 (enExample)
BR (1) BR0110211A (enExample)
CA (1) CA2406685C (enExample)
HU (1) HUP0300619A3 (enExample)
MX (1) MXPA02010325A (enExample)
NO (1) NO324868B1 (enExample)
PL (1) PL203161B1 (enExample)
RU (1) RU2275371C2 (enExample)
TW (1) TWI294877B (enExample)
WO (1) WO2001083463A1 (enExample)
ZA (1) ZA200208307B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US7825146B2 (en) 2003-07-30 2010-11-02 Shionogi & Co., Ltd. Sulfonamide derivative having isoxazole ring
WO2006047195A2 (en) * 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
KR20090007792A (ko) * 2006-05-09 2009-01-20 화이자 프로덕츠 인크. 시클로알킬아미노산 유도체 및 이들의 제약 조성물
KR100783585B1 (ko) 2006-08-22 2007-12-07 한국생명공학연구원 스탯의 활성을 저해하는 옥사다이아졸 우레아 화합물을 유효성분으로 함유하는 암의 예방 또는 치료제
ES2748599T3 (es) 2007-08-27 2020-03-17 Dart Neuroscience Cayman Ltd Compuestos terapéuticos de isoxazol
BRPI0820868A2 (pt) * 2007-12-10 2019-09-24 Actelion Pharmaceuticals Ltd composto de tiofeno fórmula(i), composição farmacêutica contendo o mesmo e uso deste para a prevenção ou tratamento de doenças ou disturbíos associados a um sistema imune ativado
AR077969A1 (es) 2009-08-31 2011-10-05 Abbott Healthcare Products Bv Derivados de (tio)morfolina comomoduladores de s1p
RU2415845C1 (ru) * 2009-10-14 2011-04-10 Государственное образовательное учреждение высшего профессионального образования "Астраханский государственный университет" (АГУ) Сульфонные производные 2-нитро-2-(3-арил-1,2,4-оксадиазол-5-ил)этана, обладающие противолепрозной и противотуберкулезной активностью
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
CN103450167A (zh) * 2012-05-28 2013-12-18 南京大学 一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
JP2022553802A (ja) 2019-10-31 2022-12-26 エスケープ・バイオ・インコーポレイテッド Ｓ１ｐ受容体モジュレーターの固体形態
CN113264899B (zh) * 2021-04-09 2022-06-14 台州学院 一种1，3，5-噁二嗪类化合物及其制备和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0003851A3 (en) 1997-07-22 2002-10-28 Shionogi & Co Pharmaceutical composition for the treatment or prevention of glomerulopathy
AU5647099A (en) * 1998-09-11 2000-04-03 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure

Also Published As

Publication number Publication date
ZA200208307B (en) 2003-10-15
US20030203940A1 (en) 2003-10-30
AU2001246916B2 (en) 2004-10-07
RU2275371C2 (ru) 2006-04-27
US6720343B2 (en) 2004-04-13
TWI294877B (enExample) 2008-03-21
KR20030019357A (ko) 2003-03-06
MXPA02010325A (es) 2003-04-25
CA2406685C (en) 2006-10-31
WO2001083463A1 (en) 2001-11-08
PL359415A1 (en) 2004-08-23
EP1277744A1 (en) 2003-01-22
CN1436179A (zh) 2003-08-13
NO20025035L (no) 2002-12-19
PL203161B1 (pl) 2009-08-31
KR100542780B1 (ko) 2006-01-11
BR0110211A (pt) 2003-06-03
HUP0300619A2 (hu) 2003-07-28
NO20025035D0 (no) 2002-10-18
US20040122066A1 (en) 2004-06-24
AU4691601A (en) 2001-11-12
EP1277744A4 (en) 2007-07-11
JP3974781B2 (ja) 2007-09-12
CA2406685A1 (en) 2002-10-17
HUP0300619A3 (en) 2006-02-28
NO324868B1 (no) 2007-12-17

Similar Documents

Publication Publication Date Title
CN1199956C (zh) 具有抗癌作用的噁二唑衍生物
CN1088706C (zh) 新型杂环酰胺化合物及其医药用途
CN1078889C (zh) 非肽类速激肽受体拮抗剂
CN1046525C (zh) 含有稠合双环的化合物及其制备方法
CN1188401C (zh) 杂环类酰胺化合物及其医药用途
CN1093124C (zh) 对PPAR－γ具有激动剂活性的取代的4－羟基－苯基alcanoic acid衍生物
CN1161333C (zh) 作为生长激素释放剂的2-羟基吲哚衍生物
CN1158254C (zh) 作为基质金属蛋白酶抑制剂的β-磺酰基异羟肟酸
HK1041486A1 (zh) 作為前列腺素e2激動劑或拮抗劑的噁唑化合物
CN1198607C (zh) 治疗或预防肾小球病的组合物
CN1344160A (zh) 用作生长激素促分泌剂的杂环芳族化合物
CN1444582A (zh) 杂环化合物,它们的制备和用途
CN1655780A (zh) 用作前列腺素受体调节剂的噻唑烷甲酰胺衍生物
CN1469871A (zh) 作为生长激素促分泌素的取代的二肽
CN1278244A (zh) 二肽腈
CN1653047A (zh) 抗炎症药物单环芳酰吡啶酮
CN1483024A (zh) Vla-4抑制剂
CN1713907A (zh) 作为二肽酰肽酶iv抑制剂的n－取代的吡咯烷衍生物
CN1273456C (zh) 噻唑和噁唑衍生物
CN1688574A (zh) 作为葡糖激酶(gk)激活剂的吲哚－3－甲酰胺
CN1658855A (zh) O－取代羟基芳基衍生物
CN1950349A (zh) 作为用于治疗或预防糖尿病的二肽基肽酶－ⅳ抑制剂的1,2,4－噁二唑衍生物
CN1845909A (zh) 作为嗜中性白细胞弹性蛋白酶抑制剂的喹喔啉衍生物及它们的用途
CN1794988A (zh) 用于治疗血管渗透性过高疾病的方法
CN101031555A (zh) 具有vap－1抑制活性的噻唑衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050504

Termination date: 20120416